Page 1917 - Williams Hematology ( PDFDrive )

1892 Part XII: Hemostasis and Thrombosis Chapter 112: Platelet Morphology, Biochemistry, and Function 1893

393. Elzie CA, Murphy-Ullrich JE: The N-terminus of thrombospondin: The domain 429. Weltermann A, et al: Large amounts of vascular endothelial growth factor at the site
stands apart. Int J Biochem Cell Biol 36(6):1090–1101, 2004. of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol 19(7):1757–1760,
394. Tuszynski GP, et al: The interaction of human platelet thrombospondin with fibrin- 1999.
ogen. Thrombospondin purification and specificity of interaction. J Biol Chem 430. Mohle R, et al: Constitutive production and thrombin-induced release of vascular
260(22):12240–12245, 1985. endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci
395. Dardik R, Lahav J: Functional changes in the conformation of thrombospondin-1 U S A 94(2):663–668, 1997.
during complexation with fibronectin or heparin. Exp Cell Res 248(2):407–414, 1999. 431. Amirkhosravi A, et al: Blockade of GPIIb/IIIa inhibits the release of vascular endo-
396. Leung LL: Role of thrombospondin in platelet aggregation. J Clin Invest 74(5): thelial growth factor (VEGF) from tumor cell-activated platelets and experimental
1764–1772, 1984. metastasis. Platelets 10:285–292, 1999.
397. Schultz-Cherry S, Murphy-Ullrich JE: Thrombospondin causes activation of latent 432. Katoh O, et al: Expression of the vascular endothelial growth factor (VEGF) receptor
transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell
Cell Biol 122(4):923–932, 1993. death caused by ionizing radiation. Cancer Res 55(23):5687–5692, 1995.
398. Silverstein RL, et al: Complex formation of platelet thrombospondin with plasmino- 433. Wartiovaara U, et al: Peripheral blood platelets express VEGF-C and VEGF which are
gen. Modulation of activation by tissue activator. J Clin Invest 74(5):1625–1633, 1984. released during platelet activation. Thromb Haemost 80(1):171–175, 1998.
399. Bouchard BA, et al: Interactions between platelets and the coagulation system, in 434. Italiano JE Jr, et al: Angiogenesis is regulated by a novel mechanism: Pro- and antian-
Platelets, edited by AD Michelson, p 229. Academic Press, San Diego, 2002. giogenic proteins are organized into separate platelet alpha granules and differentially
400. Chesney CM, Pifer D, Colman RW: Subcellular localization and secretion of factor V released. Blood 111(3):1227–1233, 2008.
from human platelets. Proc Natl Acad Sci U S A 78:5180–5184, 1981. 435. Salven P, Orpana A, Joensuu H: Leukocytes and platelets of patients with cancer con-
401. Tracy PB, Eide LL, Bowie EJ, et al: Radioimmunoassay of factor V in human plasma tain high levels of vascular endothelial growth factor. Clin Cancer Res 5(3):487–491,
and platelets. Blood 60(1):59–63, 1982. 1999.
402. Camire RM, et al: Secretable human platelet-derived factor V originates from the 436. Verheul HM, Pinedo HM: Tumor growth: A putative role for platelets? Oncologist
plasma pool. Blood 1998;92(9):3035–3041, 1982. 3(2):II, 1998.
403. Yang TL, et al: Biosynthetic origin and functional significance of murine platelet fac- 437. Cao J, et al: Angiogenic factors in human proliferative sickle cell retinopathy. Br J
tor V. Blood 102(8):2851–2855, 2003. Ophthalmol 83(7):838–846, 1999.
404. Gould WR, Silveira JR, Tracy PB: Unique in vivo modifications of coagulation factor V 438. Solovey A, et al: Sickle cell anemia as a possible state of enhanced anti-apoptotic tone:
produce a physically and functionally distinct platelet-derived cofactor: Characteriza- Survival effect of vascular endothelial growth factor on circulating and unanchored
tion of purified platelet-derived factor V/Va. J Biol Chem 279(4):2383–2393, 2004. endothelial cells. Blood 93(11):3824–3830, 1999.
405. Kane WH, Mruk JS, Majerus PW: Activation of coagulation factor V by a platelet 439. Kiuru J, et al: Cytoskeleton-dependent release of human platelet epidermal growth
protease. J Clin Invest 70:1092–1100, 1982. factor. Life Sci 49(26):1997–2003, 1991.
406. Tracy PB, Nesheim ME, Mann KG: Proteolytic alterations of factor Va bound to plate- 440. Bush AI, Martins RN, Rumble B, et al: The amyloid precursor protein of Alzheimer’s
lets. J Biol Chem 662:669, 1983. disease is released by human platelets. J Biol Chem 265(26):15977–15983, 1990.
407. Nesheim ME, et al: Isolation and study of an acquired inhibitor of human coagulation 441. Li Q, Beyreuther K, Masters CL: Alzheimer’s disease, in Platelets, edited by AD
factor V. J Clin Invest 405:415, 1986. Michelson, pp 779–789. Academic Press, San Diego, 2007.
408. Tracy PB, et al: Factor V (Quebec): A bleeding diathesis associated with a qualitative 442. Li Q, et al: Products of the Alzheimer’s disease amyloid precursor protein generated
platelet factor V deficiency. J Clin Invest 74:1221–1228, 1983, 1984. by β-secretase are present in human platelets, and secreted upon degranulation. Amer
409. Bode AP, et al: Association of factor V activity with membranous vesicles released from J Alzheimer’s Dis, 13:236–244, 1998.
human platelets: Requirement for platelet stimulation. Thromb Res 39:49–61, 1985. 443. Li QX, et al: Secretion of Alzheimer’s disease Abeta amyloid peptide by activated
410. Manfioletti G, et al: The protein encoded by a growth arrest-specific gene (gas6) is human platelets. Lab Invest 78(4):461–469, 1998.
a new member of the vitamin K-dependent proteins related to protein S, a negative 444. Li QX, et al: Proteolytic processing of Alzheimer’s disease beta A4 amyloid precursor
coregulator in the blood coagulation cascade. Mol Cell Biol 13(8):4976–4985, 1993. protein in human platelets. J Biol Chem 270(23):14140–14147, 1995.
411. Melaragno MG, Fridell YW, Berk BC: The Gas6/Axl system: A novel regulator of vas- 445. Li QX, et al: Membrane-associated forms of the beta A4 amyloid protein precursor of
cular cell function. Trends Cardiovasc Med 9(8):250–253, 1999. Alzheimer’s disease in human platelet and brain: Surface expression on the activated
412. Angelillo-Scherrer A, et al: Deficiency or inhibition of Gas6 causes platelet dysfunc- human platelet. Blood 84(1):133–142, 1994.
tion and protects mice against thrombosis. Nat Med 7(2):215–221, 2001. 446. Van Nostrand WE, et al: Protease nexin-2/amyloid beta-protein precursor in blood is
413. Chen C, et al: Mer receptor tyrosine kinase signaling participates in platelet function. a platelet- specific protein. Biochem Biophys Res Commun 175(1):15–21, 1991.
Arterioscler Thromb Vasc Biol 24(6):1118–1123, 2004. 447. Scandura JM, et al: Progress curve analysis of the kinetics with which blood coagula-
414. Gould WR, et al: Gas6 receptors Axl, Sky and Mer enhance platelet activation and tion factor XIa is inhibited by protease nexin-2. Biochemistry 36(2):412–420, 1997.
regulate thrombotic responses. J Thromb Haemost 3(4):733–741, 2005. 448. Schmaier AH, et al: Factor IXa inhibition by protease nexin-2/amyloid beta-pro-
415. Angelillo-Scherrer A, et al: Role of Gas6 receptors in platelet signaling during tein precursor on phospholipid vesicles and cell membranes. Biochemistry 34(4):
thrombus stabilization and implications for antithrombotic therapy. J Clin Invest 1171–1178, 1995.
115(2):237–246, 2005. 449. Schmaier AH, et al: Protease nexin-2/amyloid β protein precursor. A tight-binding
416. Maree AO, et al: Growth arrest specific gene (GAS) 6 modulates platelet thrombus for- inhibitor of coagulation factor IXa. J Clin Invest 92(5):2540–2545, 1993.
mation and vascular wall homeostasis and represents an attractive drug target. Curr 450. Baskin F, et al: Platelet APP isoform ratios correlate with declining cognition in AD.
Pharm Des 13(26):2656–2661, 2007. Neurology 54(10):1907–1909, 2000.
417. Saller F, et al: Role of the growth arrest-specific gene 6 (gas6) product in thrombus 451. Borroni B, et al: Microvascular damage and platelet abnormalities in early Alzheimer’s
stabilization. Blood Cells Mol Dis 36(3):373–378, 2006. disease. J Neurol Sci 203–204:189–193, 2002.
418. Deuel TF, Huang SS, Huang JS: Platelet derived growth factor: Purification, charac- 452. Davies TA, et al: Non-age related differences in thrombin responses by platelets from
terization and role in normal and abnormal cell growth, in Biochemistry of Platelets, male patients with advanced Alzheimer’s disease. Biochem Biophys Res Commun
edited by DR Phillips, MA Shuman, pp 347–375. Academic, London, 1986. 194(1):537–543, 1993.
419. Heldin CH, Westermark B: Platelet-derived growth factor: Three isoforms and two 453. Davies TA, et al: Moderate and advanced Alzheimer’s patients exhibit platelet activa-
receptor types. Trends Genet 5(4):108–111, 1989. tion differences. Neurobiol Aging 18(2):155–162, 1997.
420. Berk BC, Alexander RW: Vasoactive effects of growth factors. Biochem Pharmacol 454. Di Luca M, et al: Differential level of platelet amyloid beta precursor protein isoforms:
38:219, 1989. An early marker for Alzheimer disease. Arch Neurol 55(9):1195–1200, 1998.
421. Madtes DK, Raines EW, Ross R: Modulation of local concentrations of platelet- 455. Rosenberg RN, et al: Altered amyloid protein processing in platelets of patients with
derived growth factor. Am Rev Respir Dis 140:1118, 1989. Alzheimer disease. Arch Neurol 54(2):139–144, 1997.
422. Ross R: Peptide regulatory factors. Platelet-derived growth factor. Lancet 1:1179, 1989. 456. Devine DV, Bishop PD: Platelet-associated factor XIII in platelet activation, adhesion,
423. Doolittle RF, et al: Simian sarcoma virus onc gene, v-sis, is derived from the gene (or and clot stabilization. Semin Thromb Hemost 22(5):409–413, 1996.
genes) encoding a platelet-derived growth factor. Science 22:275, 1983. 457. McDonagh J, et al: Factor XIII in human plasma and platelets. J Clin Invest 48(5):
424. Waterfield MD, et al: Platelet-derived growth factor is structurally related to the puta- 940–946, 1969.
tive transforming protein p28-sis of simian sarcoma virus. Nature 304:35, 1983. 458. Adany R, Bardos H: Factor XIII subunit A as an intracellular transglutaminase. Cell
425. Williams LT: Signal transduction by the platelet-derived growth factor receptor. Sci- Mol Life Sci 60(6):1049–1060, 2003.
ence 89. 24:1564–1570, 1989. 459. Lorand L, Graham RM: Transglutaminases: Crosslinking enzymes with pleiotropic
426. Nagai MK, Embil JM: Becaplermin: Recombinant platelet derived growth factor, a functions. Nat Rev Mol Cell Biol 4(2):140–156, 2003.
new treatment for healing diabetic foot ulcers. Expert Opin Biol Ther 2(2):211–218, 460. Inbal A, et al: Platelets but not monocytes contribute to the plasma levels of factor XIII
2002. subunit A in patients undergoing autologous peripheral blood stem cell transplanta-
427. Maloney JP, Silliman CC, Ambruso DR, et al: In vitro release of vascular endothelial tion. Blood Coagul Fibrinolysis 15(3):249–253, 2004.
growth factor during platelet aggregation. Am J Physiol 275(3 Pt 2):H1054–H1061, 1998. 461. Serrano K, Devine DV: Intracellular factor XIII crosslinks platelet cytoskeletal ele-
428. Webb NJ, et al: Vascular endothelial growth factor (VEGF) is released from platelets ments upon platelet activation. Thromb Haemost 88(2):315–320, 2002.
during blood clotting: Implications for measurement of circulating VEGF levels in 462. Huff T, et al: Thymosin beta4 is released from human blood platelets and attached by
clinical disease. Clin Sci (Lond) 94(4):395–404, 1998. factor XIIIa (transglutaminase) to fibrin and collagen. FASEB J 16(7):691–696, 2002.

Kaushansky_chapter 112_p1829-1914.indd 1892 17/09/15 3:30 pm